LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Assay Detects Urinary Proteins in Bladder Cancer

By LabMedica International staff writers
Posted on 08 Jul 2013
Print article
Image: Synergy HT Multi-Mode microplate reader (Photo courtesy of Biotek).
Image: Synergy HT Multi-Mode microplate reader (Photo courtesy of Biotek).
A high-throughput assay has been developed for the detection of tyrosine-phosphorylated proteins (TPPs) in urine of bladder cancer patients.

Urinary TPPs appear to be a potential cancer marker for the detection of early stages of bladder cancer, but the development of methods to perform the evaluation of their diagnostic performances and their clinical validation is crucial.

Oncologists at the University of Turin Medical School (Turin, Italy) collected urine specimens from 23 bladder cancer patients and 43 healthy volunteers. There were 19 males and 4 females with bladder cancer with a mean age of 67.65 ± 10.63. The scientists developed an immobilized metal affinity chromatography (IMAC) system that was miniaturized in a 96 well format. Luminescence, visible, and infrared fluorescence antibody-based detection methods were comparatively evaluated.

The luminescence end-point detection was performed by means of a Synergy HT Multi-Mode microplate reader (Biotek; Winooski, VT, USA) and infrared (IR) fluorescence detection was performed with the Odyssey Infrared Imaging System (LI-COR Biosciences; Lincoln, NE, USA). Due to their low abundance, both a phosphoprotein enrichment step and very sensitive detection methods are required to detect TPPs in urine samples. To pursue high throughput, reproducibility and cost containment, which are required for bladder cancer screening programs. The scientists coupled the preanalytical IMAC procedure with high sensitive detection phases using either infrared fluorescence or chemiluminescence in an automated platform.

The assay represents the first quantitative and high throughput method for the measurement of TPPs in urine. Preliminary evaluation of the sensitivity and the specificity was 87% and 95% respectively, which confirmed the excellent diagnostic performances of TPPs as bladder cancer marker. The authors concluded that their method had optimized the measurement of TPP levels in urine samples, integrating the preanalytical and analytical phases in a 96 well format and with the use of affordable detection methods. This method is now feasible to be applied to a large number of patients and high-risk subjects to establish its actual diagnostic and predictive power. The study was published in the June 2013 issue of the journal Biochimica et Biophysica Acta.

Related Links:

University of Turin Medical School
Biotek
LI-COR Biosciences


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more